The core technology team consists of many senior immunotherapy experts from the University of Pennsylvania, Harvard University and other famous American immunotherapy centers and enterprises. They have engaged in the research and development, quality control, standardized production and clinical application management of immunotherapy such as CAR-T for nearly 20 years. They were important participants and senior project leaders in the early R&D (1996), production and application team of CAR-T therapy over the world. They have successfully treated Emily Whitehead, an American pediatric patient who has leukemia and they also contribute to the first FDA approved CAR-T medication for human. Their relevant findings were rated by Science magazine as the first in the world’s Top10 breakthroughs in science and technology in 2013. In addition, we have experienced team for drug evaluation and quality assurance (QA). More than 10 years of practical experiences in evaluating and monitoring of biological agents include medicines of immunocytes, which help us to be familiar with the FDA (the U.S.) and cFDA (China) and other countries and regions of the evaluation process of biological agents. Our experts have participated in the technical consultation about the policy of the national cell therapy guidance.
